4.7 Article

Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma

期刊

BMC GENOMICS
卷 23, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12864-021-08265-y

关键词

Antigen-presenting cells; High-grade serous ovarian carcinoma; Immune cell infiltration; PD-1; PD-L1

资金

  1. National Natural Science Foundation of China [82002741, 81960465, 82060471]

向作者/读者索取更多资源

The study identified a unique molecular subtype of high-grade serous ovarian carcinoma characterized by high antigen-presenting cell infiltration, with immune cell infiltration cluster C showing improved prognosis and higher sensitivity to immunotherapy. The programmed death-1/programmed death ligand 1 expression can help classify molecular subtypes and determine prognosis and treatment response.
Background High-grade serous ovarian carcinoma is highly heterogeneous, and although many studies have been conducted to identify high-grade serous ovarian carcinoma molecular subtypes that are sensitive to immunotherapy, no precise molecular subtype has been proposed to date. Immune cell infiltration and immune checkpoints are highly correlated with immunotherapy. Here, we investigated immune cell infiltration and immune checkpoint values for prognosis and precise immunotherapy for high-grade serous ovarian carcinoma based on molecular subtype classification. Results High antigen-presenting cells infiltration molecular subtype of high-grade serous ovarian carcinoma was identified in immune cell infiltration profiles. Each of the three immune cell infiltration clusters (A, B, and C) demonstrated distinct immune cell characterization, with immune cell infiltration cluster C exhibiting high antigen-presenting cell infiltration, improved prognosis, and higher sensitivity to immunotherapy. Programmed death-1/programmed death ligand 1 has a prognostic and predictive role that can help classify molecular subtypes. Conclusions Our findings redefined a unique molecular subtype of high-grade serous ovarian carcinoma, suggesting that high-grade serous ovarian carcinoma patients with higher antigen-presenting cell infiltration and programmed death-1/programmed death ligand 1 expression can benefit from precise immunotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据